GlobeNewswire Clinical StudiesOriginal article
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Phase 1positiveAP02Positive
AI Analysis
Summary
Avalyn published Phase 1 data for AP02 demonstrating lung-targeted delivery of antifibrotic medicines with an encouraging safety profile, validating the company's approach to maximize local lung exposure while minimizing systemic exposure.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
Lung-targeted delivery demonstrated with encouraging safety profile
Importance:6/10
Sentiment:
0.70
Phase 1 dataPulmonary deliverySafetyAntifibroticData publication
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on September 21, 2026 1:00 PM